Edgewise Therapeutics sells sevasemten to Servier for up to $2.65 billion

June 1, 2026 8:31 AM

Edgewise Therapeutics Inc. (NASDAQ: EWTX) announced it entered into a definitive agreement to sell sevasemten and its muscular dystrophy business ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found